Non-systemic Treatment for Patients With Low-volume Metastatic Prostate Cancer

Inclusion Criteria: * Histologically proven diagnosis of prostate cancer (PCa) * Biochemical relapse of PCa following radical local prostate treatment * N1 and M1a/b disease on imaging, with a combined maximum of 3 synchronous lesions. * World Health Organization (WHO) performance state 0-1 * Exclusion of local relapse * Age \>=18 years old * Signed informed consent Exclusion Criteria: * Serum testosterone level \<50ng/ml * Symptomatic metastases * PSA rise while on active treatment with luteinizing hormone-releasing hormone (LHRH)-agonist, LHRH-antagonist, anti-androgen, maximal androgen blockade, oestrogen * Previous treatment with cytotoxic agent for PCa * Treatment during the past month with products known to influence Prostate Specific Antigen (PSA) levels (e.g. fluconazole, finasteride, corticosteroids,…) * Disorder precluding understanding of trial information or informed consent